Depression News

Beckley Psytech announced dosing of the first patient in a phase 2b clinical trial of BPL-003, an intranasal synthetic formulation of the psychedelic compound 5-MeO-DMT for treatment-resistant depression.

Ajovy significantly reduced depression symptoms and monthly migraine days in a phase 4 study, with clinically meaningful improvements in disability outcomes, manufacturer Teva Pharmaceuticals announced in a press release.

Women were nearly 50% more likely to develop depression after experiencing traumatic brain injury compared with men, according to a study presented at the American Society of Anesthesiologists annual meeting.

DALLAS — Initiation and continued use of certain antidepressants may cause more weight gain over 2 years, according to research presented at ObesityWeek.

The association between the prevalence of cannabis use and depression among young adults strengthened following the legalization of recreational cannabis, according to researchers.

Researchers observed lower levels of perceived stress among women with MI with nonobstructive coronary arteries vs. those with MI and CAD, but the prevalence of depressive symptoms was similar.

A commonly used depression screening tool was better at identifying patients who would attempt suicide in the next 3 months than screening tools specifically asking about suicidal ideation, according to an expert.

In a statement, the American Psychiatric Association condemned the recent terrorist attacks in Israel and offered support and mental health resources to those affected by these unfolding events.

A study of more than 110,000 patients receiving psychotherapy found improved continuity of care and significantly fewer days between appointments after the switch to virtual care during the COVID-19 pandemic.

The prevalence of neuropsychiatric symptoms in patients with systemic autoimmune rheumatic diseases is significantly “higher and more wide-ranging” than previously recognized, according to data published in Rheumatology.